- Cancer Institute
- Cancer Research
- Cancer Registries
- Mississippi Cancer Registry
- Resources
- Reportable Diseases
Reportable Diseases
- Cancer Center and Research Institute
-
Cancer Research
- Cancer Research Overview
-
Cancer Registries
- Cancer Registries Home
- UMMC Cancer Registry
- Mississippi Cancer Registry
- Clinical Trials
- Programs
- For Students and Trainees
- Patient Support
- Give Now
- In the News
- Contact Cancer Center and Research Institute
- CCRI Leadership
Main Content
Reportable Cancer List DX 10/2013 or later
REPORTABLE CASES – MISSISSIPPI
For cases diagnosed 10/1/2013 and forward
The following lists are intended to assist you, as the reporter, in identifying the reportable neoplasms for your facility. Any reportable neoplasms diagnosed on or after January 1, 1996 should be reported to the Mississippi Cancer Registry.
REPORTABLE NEOPLASMS
- Malignant neoplasms (exclusions noted below)
- Benign and borderline neoplasms of the central nervous system (Cases diagnosed on or after January 1, 2004)
- Carcinoma in-situ (exclusions noted below)
- Carcinoid, NOS (excluding appendix, unless stated to be malignant)
- Pilocytic/juvenile astrocytoma is listed as 9421/1 in ICD-O-3, is reportable, and should be coded to 9421/3.
- Squamous intraepithelial neoplasia grade III of vulva [VIN], vagina [VAIN], and anus [AIN] beginning with 2001 cases.
NON-REPORTABLE NEOPLASMS
- Basal and squamous cell carcinomas of the skin (ICD-O-3 Histologies 8090-8110)
- Epithelial carcinomas of the skin (ICD-O-3 Histologies 8010-8046)
- Papillary and squamous cell carcinomas of the skin (ICD-O-3 Histologies 8050-8084)
- Malignant neoplasms, NOS of the skin (ICD-O-3 Histologies 8000-8005)
- Carcinoma in-situ of the cervix
- Intraepithelial neoplasms of the cervix (ICD-O-3 Histology 8077/2) or prostate (ICD-O-3 Histology 8148/2)
- Borderline cystadenomas (ICD-O-3 Histologies 8442, 8451, 8462, 8472, 8473), of the ovaries with behavior code "1" are not collected as of January 1, 2001
- Cyst, brain or CNS tumor that does not have an ICD-O-3 code as of January 1, 2004
AMBIGUOUS TERMINOLOGY
| Terms That Constitute a Diagnosis | Terms That Do Not Constitute a Diagnosis |
| Apparent(ly) | Cannot be ruled out |
| Appears to | Equivocal |
| Comparable with | Possible |
| Compatible with | Potentially malignant |
| Consistent with | Questionable |
| Favor(s) | Rule out |
| Malignant appearing | Suggests |
| Most likely | Worrisome |
| Presumed | |
| Probable | |
| Suspect | |
| Suspicious | |
| Typical of | |
| Tumor (beginning with 2004 diagnosis andonly for C70.0-C72.9, C75.1-C75.3) | |
| Neoplasm (beginning with 2004 diagnosis and only for C70.0-C72.9, C75.1-C75.3) |
Exceptions:
- If a cytology is reported using any ambiguous term, do not interpret it as a diagnosis of cancer. Abstract the case only if a positive biopsy or a physician's clinical impression of cancer supports the cytology findings.
- Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.
There are other ambiguous terms used by physicians that are related to staging. Some may indicate tumor involvement or extension, while others are not considered to be involvement. Refer to Collaborative Staging Manual and Coding Instructions for a listing of those terms.
COMPREHENSIVE ICD-9-CM CASEFINDING CODE LIST FOR REPORTABLE TUMORS
| ICD-9-CM Codes | Diagnosis |
| Code Ranges | Explanation of Code |
| 140._ - 172._, 174._-209.36, 209.7_ | Malignant neoplasms (excluding category 173) stated or presumed to be primary (of specified sites) and certain specified histologies |
| 173.00, 173.09 | Unspecified/other malignant neoplasms of skin of lip |
| 173.10, 173.19 | Unspecified/other malignant neoplasm of eyelid, including canthus |
| 173.20, 173.29 | Unspecified/other malignant neoplasm of ear and external auricular canal |
| 173.30, 173.39 | Unspecified/other malignant neoplasm of skin of other/unspecified parts of face |
| 173.40, 173.49 | Unspecified/other malignant neoplasm of scalp and skin of neck |
| 173.50, 173.59 | Unspecified/other malignant neoplasm of skin of trunk, except scrotum |
| 173.60, 173.69 | Unspecified/other malignant neoplasm of skin of upper limb, including shoulder |
| 173.70, 173.79 | Unspecified/other malignant neoplasm of skin of lower limb, including hip |
| 173.80-173.89 | Unspecified/other malignant neoplasm of other specified sites of skin |
| 173.90, 173.99 | Unspecified/other malignant neoplasm of skin, site unspecified |
| 225.0 - 225.9 | Benign Neoplasms of brain and spinal cord |
| 227.3, 227.4 | Benign neoplasm of pituitary gland, craniopharyngeal duct (pouch) and pineal gland |
| 228.02 | Hemangioma; of intracranial structures |
| 228.1 | Lymphangioma, any site (Note: Only lymphangiomas of the brain, other parts of nervous system and endocrine gland are reportable) |
| 230.0 - 234.9 | Carcinoma In Situ (Includes AIN III, VIN III and VAIN III) |
| 237.0 - 237.1 | Neoplasm of uncertain behavior of endocrine glands and nervous system: pituitary gland, craniopharyngeal duct and pineal gland |
| 237.5, 237.6, 237.9 | Neoplasm of uncertain behavior of endocrine glands & nervous system: brain & spinal cord, meninges, endocrine glands & other & unspec. parts of nervous system |
| 238.4 | Polycythemia vera |
| 238.7_ | Other lymphatic and hematopoietic diseases |
| 239.6, 239.7 | Neoplasms of unspecified nature, brain, endocrine glands and other parts of nervous system |
| 273.3 | Macroglobulinemia (Waldenstrom's macroglobulinemia) |
| 277.89 | Other specified disorders of metabolism (Reportable includes terms: Hand-Schuller-Christian disease; histiocytosis (acute)(chronic); histiocytosis X (chronic)) |
SUPPLEMENTAL CASEFINDING LIST TO BE SCREENED FOR REPORTABLE CONDITIONS
Cases with the following codes should be screened as time allows. Experience has shown that use of this supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms and other reportable diseases
| Individual ICD-9-CM Codes | Explanation of Code |
| 042 | Acquired Immunodeficiency Syndrome (AIDS) Note: Screen 042 for history of cancers with HIV/AIDS |
| 079.51 – 079.53 | Retrovirus (HTLV, types I, II and 2) |
| 173.01, 173.02 | Basal and squamous cell carcinoma of skin of lip |
| 173.11, 173.12 | Basal and squamous cell carcinoma of eyelid, including canthus |
| 173.21, 173.22 | Basal and squamous cell carcinoma of ear and external auricular canal |
| 173.31, 173.32 | Basal and squamous cell carcinoma of skin of other and unspecified parts of face |
| 173.41, 173.42 | Basal and squamous cell carcinoma of scalp and skin of neck |
| 173.51, 173.52 | Basal and squamous cell carcinoma of skin of trunk, except scrotum |
| 173.61, 173.62 | Basal and squamous cell carcinoma of skin of upper limb, including shoulder |
| 173.71, 173.72 | Basal and squamous cell carcinoma of skin of lower limb, including hip |
| 173.81, 173.82 | Basal and squamous cell carcinoma of other specified sites of skin |
| 173.91, 173.92 | Basal and squamous cell carcinoma of skin, site unspecified |
| 209.40 - 209.69 | Benign carcinoid tumors |
| 210.0 - 229.9 | Benign neoplasms (except for 225.0-225.9, 227.3, 227.4, 228.02, 228.1, which are listed in the Reportable list)Note: Screen for incorrectly coded malignancies |
| 235.0 – 236.99 | Neoplasm of uncertain behavior of adrenal gland, paraganglia and other and unspecified endocrine glands Note: screen for incorrectly coded malignancies |
| 237.2 – 237.4 | Neoplasm of uncertain behavior of adrenal gland, paraganglia and other and unspecified endocrine glands Note: screen for incorrectly coded malignancies |
| 237.7_ | Neurofibromatosis and Schwannomatosis |
| 238.0 – 239.9 | Neoplasms of uncertain behavior (except for 238.4, 238.71-238.79, 239.6, 239.7, which are listed in the reportable list) Note: Screen for incorrectly coded malignancies |
| 259.2 | Carcinoid syndrome |
| 273.0 | Polyclonal hypergammaglobulinemia (Note: screen for blood disorders due to neoplasm) |
| 273.1 | Monoclonal gammopathy of undetermined significance (9765/1) Note: Screen for incorrectly coded Waldenstrom macroglobulinemia or progression |
| 273.2 | Other paraproteinemias |
| 273.8, 273.9 | Other and unspecified disorders of plasma protein metabolism Note: includes plasma disorders due to neoplastic disease |
| 275.42 | Hypercalcemia (Note: Includes hypercalcium due to neoplastic disease) |
| 277.88 | Tumor lysis syndrome (following neoplastic chemotherapy) |
| 284.1_ | Pancytopenia (Note: screen for anemia disorder related to neoplasm) |
| 285.22 | Anemia in neoplastic disease |
| 285.3 | Anemia due to antineoplastic chemotherapy |
| 287.39, 287.49, 287.5 | Secondary, other primary and unspecified thrombocytopenia Note: Screen for incorrectly coded thrombocythemia |
| 288.03 | Drug induced neutropenia (note: screen for anemia disorder related to neoplasm) |
| 288.3 | Eosinophilia (Note: Code for eosinophilia (9964/3). Not every case of eosinophilia is with a malignancy. Diagnosis must be "Hypereosinophilic syndrome" to be reportable.) |
| 288.4 | Hemophagocytic syndrome |
| 338.3 | Neoplasm related pain (acute)(chronic) |
| 528.01 | Mucositis due to antineoplastic therapy |
| 530.85 | Barrett's esophagus (High grade dysplasia of esophagus) |
| 569.44 | Dysplasia of anus (Anal intraepithelial neoplasia [AIN I and II]) |
| 602.3 | Dysplasia of prostate (Prostatic intraepithelial neoplasia [PIN Iand II]) |
| 622.10 – 622.12 | Dysplasia of cervix, unspecified and CIN I, CIN II |
| 623.0 | Dysplasia of vagina (Vaginal intraepithelial neoplasia [VAIN Iand II] |
| 624.01, 624.02 | Vulvar intraepithelial neoplasia: unspecified, VIN I and VIN II |
| 630 | Hydatidiform mole (Note: benign tumor that can become malignant. If malignant, it should be reported as Choriocarcinoma (9100/3) with malignancy code in 140-209 range) |
| 785.6 | Enlargement of lymph nodes |
| 780.79 | Neoplastic (malignant) related fatigue |
| 789.51 | Malignant ascites |
| 790.93 | Elevated prostate specific antigen (PSA) |
| 793.8_ | Nonspecific (abnormal) findings on radiological & examination of body structure (breast) |
| 795.0_ - 795.1_ | Papanicolaou smear of cervix and vagina with cytologic evidence of malignancy |
| 796.7_ | Abnormal cytologic smear of anus and anal HPV |
| 795.8_ | Abnormal tumor markers; Elevated tumor associated antigens [TAA] |
| 963.1 | Poisoning by primarily systemic agents: antineoplastic and immunosuppressive drugs |
| 990 | Effects of radiation, unspecified (radiation sickness) |
| 999.3_ | Complications due to central venous catheter |
| E858.0 | Accidental poisoning by other drugs: Hormones and synthetic substitutes |
| E858.1 | Accidental poisoning by other drugs: Primary systemic agents |
| E858.2 | Agents primarily affecting blood constituents |
| E873.2 | Failure in dosage, overdose of radiation in therapy (radiation sickness) |
| E879.2 | Overdose of radiation given during therapy (radiation sickness) |
| E930.7 | Adverse reaction of antineoplastic therapy-Antineoplastic antibiotics |
| E932.1 | Adverse reaction to antineoplastic therapy-Androgens and anabolic congeners |
| E933.1 | Adverse effect (poisoning) of immunosuppressive drugs |
| V10.0_ – V10.9_ | Personal history of malignancy Note: Screen for recurrences, subsequent primaries, and/or subsequent treatment |
| V12.41 | Personal history of benign neoplasm of the brain |
| V13.89 | Personal history of unspecified. malignant neoplasm, history of in-situ neoplasm of other site |
| V15.3 | Other personal history presenting hazards to health or (therapeutic) radiation |
| V42.81, V42.82 | Organ or tissue replaced by transplant: Bone marrow, peripheral stem cells |
| V51.0 | Encounter for breast reconstruction following mastectomy |
| V58.0, V58.1_ | Encounter for radiotherapy, chemotherapy, immunotherapy |
| V66.1, V66.2 | Convalescence and palliative care following radiotherapy, chemotherapy |
| V66.7 | Encounter for palliative care |
| V67.1, V67.2 | Follow up examination: following radiotherapy or chemotherapy |
| V71.1 | Observation for suspected malignant neoplasm |
| V76._ | Special screening for malignant neoplasms |
| V86._ | Estrogen receptor positive status [ER+], negative status [ER-] |
| V87.41 | Personal history of antineoplastic chemotherapy |
| V87.43 | Personal history of estrogen therapy |
| V87.46 | Personal history of immunosuppression therapy |